Product Description
Rimegepant is used to prevent and treat the symptoms of migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light). Rimegepant is in a class of medications called calcitonin gene-related peptide receptor antagonists.
Mechanisms of Action: CGRP Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Chile | Croatia | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Lithuania | Luxembourg | Mexico | Norway | Philippines | Poland | Portugal | Romania | Slovakia | Spain | Sweden | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, Czech Republic, Finland, France, Hubei Province, Hungary, Italy, Japan, Korea, Mexico, Poland, Slovakia, Spain, Sweden, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 28
Highest Development Phases
Phase 3: Migraine Disorders|Migraine with Aura|Migraine without Aura|Nasal Polyposis|Sinusitis
Phase 2: Irritable Bowel Syndrome|Psoriasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Acute Treatment | P3 |
Recruiting |
Migraine Disorders |
2029-01-09 |
|
| jRCT2051240163 | P3 |
Not yet recruiting |
Migraine Disorders |
2028-07-11 |
|
| C4951013 | P3 |
Unknown Status |
Migraine Disorders |
2027-12-02 |
|
| BHV3000-312 | P3 |
Recruiting |
Migraine Disorders |
2027-06-09 |